Microphthalmia-associated transcription factor (Mitf) is critically involved in melanin synthesis as well as differentiation of cells of the melanocytic lineage. Some earlier studies suggested that Mitf is also essential in the survival of melanoma cells, but this notion remains controversial. We synthesized short interfering RNA (siRNA) duplexes corresponding to the mitf sequence and transfected them into B16 melanoma. Lipid-mediated transfection in vitro of Mitfspecific siRNA resulted in specific downregulation of Mitf and of the tyrosinase that is a transcriptional target of Mitf. This treatment also remarkably reduced the viability of melanoma cells by inducing apoptosis. To examine the potential feasibility of RNAi therapy against melanoma, B16 cells were subcutaneously injected into syngenic mice and siRNA was transfected into the pre-established tumor by means of electroporation. The Mitf-specific siRNA drastically reduced outgrowth of subcutaneous melanoma, while nonspecific siRNA failed to affect tumor progression. Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling-based analysis of tumor specimens demonstrated that the tumor cells transfected with Mitf-siRNA effectively underwent apoptosis in vivo. The present results indicate that Mitf plays important roles in melanoma survival. Intratumor electrotransfer of Mitf-specific siRNA may provide a powerful strategy for therapeutic intervention of malignant melanoma.
Introduction
Malignant melanoma is an extremely malignant neoplasm originating from melanocytes. Although the cause of melanoma has not fully been elucidated, ultraviolet exposure is considered etiologically involved in the generation of this malignancy. The melanoma is relatively frequent among Caucasian populations, although the incidence of melanoma is also increasing in nonCaucasians. Surgery is effective for the treatment of early stages of melanoma, while chemotherapy and/or radiation are applied to advanced melanoma patients with inoperable multiple organ metastases. Unfortunately, conventional non-surgical procedures are usually ineffective for melanoma, because the tumor cells are highly resistant to irradiation and chemotherapeutic agents, so that the prognosis of advanced melanoma patients is extremely poor. On the other hand, malignant melanoma is potentially immunogenic, as demonstrated by the identification of a variety of melanoma-associated antigens. 1 A variety of immunotherapeutic strategies have been devised, including adoptive transfer of effector cells, 2 immunization with tumor cell vaccines 3 and vaccination with dendritic cells pulsed with antigen peptides and/or tumor lysate. 2, 4 Nevertheless, clinical outcome of immunotherapy remains insufficient, due, at least partly, to tumor escape phenomena such as downmodulation of major histocompatibility complex class I expression, 5 and induction of regulatory T cells and regulatory cytokines. 2, 6 Therefore, novel, effective and safe therapeutic procedures are desired to eradicate malignant melanoma.
In this context, therapeutic molecular targeting may provide a promising measure to treat malignancies, by specifically suppressing the molecules that play crucial roles in growth and survival of melanoma.
The microphthalmia-associated transcription factor (Mitf) belongs to the family of transcription factors with a basic-helix-loop-helix-leucine-zipper motif. 7, 8 The Mitf consists of at least seven isoforms, referred to as Mitf-M, A, B, C, D, E and H, which differ from each other at their amino-termini corresponding to alternative spliced forms of a single gene. Among them, Mitf-M is specifically expressed in melanocytes and melanomas, 9 while other isoforms are also expressed in retinal pigment epithelium (Mitf-A, B, C, D and H), H). 13, 14 Through binding to the specific recognition motif, that is, the M box sequence (CATGTG), Mitf enhances transcription of the genes encoding major enzymes in the melanin synthesis pathway, including tyrosinase, 15, 16 tyrosinase-related protein 1 (TRP-1), 16 TRP-2 11 and dopachrome tautomerase 17 as well as other melanogenic genes, such as SILV/PMEL17/GP100 and MLANA/MART-1. 18 Mutations in the Mitf gene result in the loss or anomaly of pigmentation in mouse 8, 19 and human 20, 21 owing to aberrant differentiation of melanocytes. It has also been reported that fibroblasts genetically transfected with Mitf develop into cells with characteristics of melanocytes. 22 Therefore, Mitf is a key transcriptional factor that is crucially involved in melanocytogenesis. 17, 23, 24 Importantly, Mitf may contribute to cell cycle progression as well as viability of melanocytes and melanomas. However, it remains controversial whether Mitf functions as a positive or negative regulator for melanoma proliferation and survival. By transfecting dominantnegative (DN) mutant of Mitf into melanoma, McGill et al. 25 demonstrated that Mitf upregulates Bcl2 and blocks apoptosis of the tumor cell. Du et al. 26 showed that suppression of Mitf inhibits CDK2 expression, leading to cell cycle arrest and growth inhibition. Garraway et al. 27 documented that Mitf may be involved in malignant transformation of melanocytes and survival of melanoma in cooperation with BRAF, while DN Mitf renders melanoma cells susceptible to chemotherapeutic agents. Although these reports indicate that Mitf promotes survival and growth of melanoma, other studies suggest different conclusions. Overexpression of Mitf-M reportedly suppresses growth of MITF-M-deficient melanocytes, 28 while Mitf is involved in cyclic adenosine mono phosphate-induced growth suppression in melanoma and melanocytes. 29 Larribere et al. 30 demonstrated that an apoptotic signal cleaves Mitf to generate the C fragment that induces apoptosis in melanoma, suggesting that the Mitf is a component of proapoptotic signal transduction. Mitf has also been shown to upregulate p16
INK4a which inactivates retinoblastoma protein (Rb) and suppresses proliferation of melanocytes and fibroblasts, although this regulatory mechanism is disrupted in the melanoma cells carrying p16 INK4a mutation. 31 Carreira et al. 32 reported that Mitf cooperates with Rb to induce p21 cip1 expression, resulting in G1 arrest and growth inhibition of melanoma.
In the present study, we synthesized short interfering RNA (siRNA) duplexes targeting the Mitf cDNA sequence and delivered them into B16 melanoma in culture. Pre-established B16 tumors in mice were also transfected with Mitf-siRNA to evaluate the potential feasibility of Mitf-siRNA as a novel molecular medicine in melanoma treatment.
Results
Mitf-specific siRNA suppressed expression of Mitf in B16
We designed six siRNA duplexes based on the murine Mitf gene sequence (Mitf-siRNAs-1 to 6) and transfected them into B16 cells in culture using the RNAiFect as a vehicle. As controls, some aliquots of cells were transfected with siRNA specific for enhanced green fluorescent protein (EGFP), while other groups were left untreated or incubated with RNAiFect alone. After 6 h, the Mitf mRNA levels were assessed by real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis to evaluate the silencing effect of each Mitf-siRNA. As shown in Figure 1a , the Mitf message in B16 was reduced to 39-58% after transfection with a Mitf-siRNA duplex. Similar results were also obtained when Mitf mRNA was examined 24 h after transfection with Mitf-siRNA-2 ( Figure 1b) .
Western blot analysis was also performed to detect Mitf protein. As shown in Figure 1c , Mitf appeared as two bands of molecular weight of approximately 52-56 kDa, which was in consistent with the description in some previous reports. 33, 34 Intensity of the Mitf signal was remarkably diminished in the B16 cells after treatment with Mitf-siRNA-2, strongly suggesting that the siRNA treatment successfully suppressed the expression of Mitf protein in melanoma.
siRNA-mediated knockdown of Mitf significantly suppressed growth of B16 melanoma in culture
We assessed whether transcriptional silencing of Mitf affected viability of B16 in vitro. B16 cells were transfected with Mitf-siRNA as above, and 48 h later cell numbers were counted. As shown in Figure 2a , the number of cells transfected with control siRNA did not In contrast, the cell number was significantly decreased after transfection with Mitf-siRNAs-1, 2, 3 and 5, while the Mitf-siRNA-4 induced less significant reduction in cell count. MitfsiRNA-6 failed to show statistically significant effects on the number of melanoma cells. Similar results were obtained in another experiment in which tetrazolium salt-based analysis revealed that Mitf-siRNAs-1 and 2 drastically decreased the viability of B16, while MitfsiRNAs-3 and 5 were less effective in influencing the cell fate ( Figure 2b ). Cells transfected with Mitf-siRNAs-4 and 6 showed comparable viability with the cells given control siRNA. These findings indicated that RNAimediated silencing of Mitf suppressed viability of B16 melanoma in vitro, although the degrees of suppression varied depending on the sequences of the siRNAs used. The silencing effect of Mitf was further investigated in the following experiments in which the Mitf-siRNA-2 was delivered into B16 at various doses, and cell number and viability were evaluated after cultivation for various time periods. As shown in Figure 3a , the cells transfected with EGFP-siRNA showed a moderate decrease in cell number during the initial 12 h, after which the cells started to proliferate. The temporal suppression of cell growth may reflect nonspecific effects caused by siRNA transfer into cells. In contrast, the transfection with MitfsiRNA-2 drastically reduced the B16 cell number by 12 h, and virtually all the cells were dead 48 h after transfection (P-values at 48 h are: Po0.005, 2 mg of MitfsiRNA-2 vs non-treated; Po0.001, 2 mg of Mitf-siRNA-2 vs vehicle; Po0.005, 2 mg of Mitf-siRNA-2 vs 2 mg of EGFP-siRNA) ( Figure 3a) . These results were confirmed by the tetrazolium-based assay, which demonstrated that the EGFP-siRNA groups showed a transient and moderate reduction in cell viability, while the transfection with Mitf-siRNA-2 triggered a sharp fall in the viability of melanoma cells (P-values at 24 h are: Po0.00005, 0.5 mg of Mitf-siRNA-2 vs vehicle; Po0.005, 0.5 mg of Mitf-siRNA-2 vs 0.5 mg of EGFP-siRNA) ( Figure 3b ). The remarkable cytotoxic effect was obtained even after transfection with small doses of the siRNA duplex (2 mg/10 5 cells in Figure 3a , and 0.5 mg/3.3 Â 10 4 cells in Figure 3b ). The findings clearly demonstrated that the Mitf-specific siRNA efficiently killed B16 melanoma cells in culture.
To examine whether the tumoricidal activity of MitfsiRNA-2 is specific for melanoma, LL/2 murine lung carcinoma cells were also transfected with the siRNA duplex, followed by evaluation of cell number and viability. It was found that the suppressive activity of Mitf-siRNA-2 was very low, if any, in this tumor cells (data not shown).
Mitf-specific siRNA induced apoptotic death of B16 melanoma in vitro
To assess whether the decrease in viability of MitfsiRNA-transfected cells is due to apoptosis, we performed the terminal deoxynucleotidyl transferasemediated dUTP-biotin nick end labeling (TUNEL)-based analysis of B16 cells after siRNA transfection. Figure 4 shows the representative views obtained from fluorescent and phase contrast microscopic observation. MitfsiRNA-2
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Approximately 25% of the Mitf-siRNA-2-transfected B16 cells underwent apoptosis, while control cells were virtually intact regardless of whether they were treated with control siRNA or not. The results clearly indicate that the tumoricidal activity in vitro of Mitf transcriptional silencing may be predominantly ascribed to apoptosis induction in melanoma cells.
Tyrosinase was downregulated by siRNA targeting Mitf
It has been reported that tyrosinase is transcriptionally regulated by Mitf in melanoma cells. 15 To examine whether the Mitf-specific siRNA suppressed the transcriptional activity of the DNA-binding protein, we measured the tyrosinase activity in B16 after treatment with Mitf-siRNA-2. As shown in Figure 5 , the enzyme activity was considerably reduced by Mitf-siRNA-2, while the cells treated with vehicle alone or nonspecific siRNA did not show any significant reduction in the tyrosinase level in comparison with untreated cells. It was strongly suggested that the siRNA-mediated knockdown of Mitf induced functional attenuation of the transcriptional factor.
Electroporation-mediated transfection with Mitf-siRNA significantly suppressed pre-established B16 tumor in mice
Based on the in vitro data above, we investigated whether the Mitf-specific siRNA is capable of inhibiting growth of melanoma in vivo, using mice bearing subcutaneous B16 tumor. To distribute siRNA to broad areas in each tumor, two aliquots of siRNA (20 mg each) were injected sequentially into a tumor, and each injection was immediately followed by repetitive electroporation. The treatment Electro-RNAi-therapy of melanoma targeting Mitf N Nakai et al was performed daily for 10 days. As shown in Figure 6 , untreated melanomas displayed rapid and continued outgrowth in mice, while virtually the same growth curve was shown by the tumors treated with phosphatebuffered saline (PBS 
Discussion
The present study demonstrated that specific silencing of Mitf by means of RNAi induced a significant cytotoxic 49 Compared with these target genes, Mitf is specific for melanomas and melanocytes, especially when Mitf-M isotype-specific sequence is targeted. This may guarantee the safety of patients when the Mitf RNAi will be put into a clinical trial. Another advantage of the Mitf knockdown therapy is that Mitf silencing may induce apoptosis of tumor cells rather than cytostatic effects, while specific silencing of angiogenic or cell cycle-regulatory genes may have reversible influence on tumor cells. A combination therapy targeting more than two genes may elicit more promising results.
One of the major issues of RNAi cancer therapeutics is on the efficacy and safety of delivery systems to transfer siRNA into tumor cells. Retroviral, 50 adenoviral, 51 adeno-associated viral 52 and lentiviral 40 vectors engineered to express siRNA have been proposed, taking advantage of high rate transfection in vivo into tumor cells. 36, 39 Moreover, viral vectors may enable relatively persistent RNAi effect in comparison with transient gene silencing obtained by synthetic siRNA duplexes. The major disadvantage of viral vectors, however, is the potential side effects associated with the vectors, such as triggering of inflammatory responses (e.g. adenoviral vector) that hinder repetitive administrations into a patient, and possible oncogenicity caused by retrovirusmediated aberration of chromosomal integrity. Nonviral transfection with synthetic siRNA is free from virusassociated adverse effects, while the RNAi effect may be transient. 43, 53, 54 Although the most appropriate delivery system should be selected for each RNAi therapeutic application, electrotransfer of synthetic siRNA may be suitable for Mitf-knockdown therapy for melanoma, because long-lasting silencing effects are not always required to kill tumor cells that have been successfully transfected with siRNA.
The electroporation method has been widely used to deliver plasmid DNA in vivo into a variety of organs/ tissues, [55] [56] [57] [58] as well as solid tumors including melanoma. 55, 56, [59] [60] [61] Electroporation was applied to RNAi by Pekarik et al. 62 who transfected synthetic siRNA in ovo into chick embryos, while we first documented electrotransfer of siRNA into a mammalian organ in vivo. 53 We also employed electroporation to therapeutic RNAi for rheumatoid arthritis in rat, indicating that the articular disorder was drastically ameliorated by silencing tumor necrosis factor-a in inflammatory sinovial tissue. 43 An advantage of electroporation is that the siRNA can be exclusively introduced into the cells that reside in the portion between the electrodes. Electroporation has been clinically used to administer chemotherapeutic agents into tumors of patients, who suffer from head and neck carcinomas, 63 basal cell carcinomas 64, 65 as well as malignant melanoma (electrochemotherapy), 64, 66 demonstrating that electroporation can be safely applied to patients. Electroporation may be repetitively applied to cancer patients without causing any serious adverse effects. The repetitive treatment should be quite important, because transfection efficiencies achieved by a single trial hardly reach 100%. The tumor cells that fail to be transfected with siRNA may survive the treatment, but in case repetitive therapy is conducted the residual tumor cells may be killed by subsequent treatments. In our experiments, Mitf-siRNA-2 treatment for only initial 10 days successfully suppressed growth of pre-established tumors in mice, without showing any sign of side effect ( Figure 6 ). Further frequent treatments with siRNA may lead to more prominent therapeutic outcomes. Other nonviral procedures, including sonoporation 67 and synthetic vectors, 54, 68 may also allow repetitive treatments for a melanoma patient.
Despite the moderate degree of silencing activity shown in the in vitro experiments (Figure 1a ), MitfsiRNA-2 exerted disproportionately strong tumor-killing activity in vivo ( Figure 6 ). This discrepancy may also be explained by an accumulation of RNAi effect resulted from the plural treatments, because in Figure 1a , mRNA was examined after a single transfection with MitfsiRNA-2, while the intratumoral transfection was performed 10 times in Figure 6 .
A single treatment in vitro with Mitf-siRNA-2 resulted in approximately 44% reduction in Mitf mRNA level (Figure 1a) , while the same treatment caused only 29% decrease in Mitf transcriptional activity as indicated by the tyrosinase assay ( Figure 5 ). This may be because the amount of Mitf protein did not fall very rapidly after degradation of Mitf mRNA, although the half-life of the protein has not been unveiled.
In conclusion, the present results strongly suggest that Mitf is an important therapeutic target for malignant melanoma, and electroporation-mediated intratumor delivery of siRNA duplex may become effective means to treat the neoplasm. Green fluorescent protein-specific siRNA was purchased from iGENE (Tsukuba, Ibaragi, Japan). 53 
Materials and methods

Cells and siRNA transfection in vitro
The murine melanoma cell line, B16, was maintained in Rosewell Park Memorial Institute medium 1640 (Nacalai Tesque, Kyoto, Japan) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum. 59 To transfect B16 in vitro, the siRNA duplex was incubated with RNAiFect (Qiagen, Hilden, Germany) and the resultant complex was added to B16 cell cultures according to the manufacturer's protocol. Cells were then incubated at 371C in 5% CO 2 /95% humidified air (standard conditions) before analysis.
Tyrosinase activity
The tyrosinase activity was measured as described elsewhere. 69 Briefly, B16 cells were seeded into 12-well plates at a density of 1 Â 10 5 per well. The next day 2 mg siRNA was transfected into the cells by means of RNAiFect as above. Cells were incubated under standard conditions for 6 h. Cells were then lysed in 45 ml of 1% Triton X-100/PBS and the extract was centrifuged at 1300 Â g. Triplicate 35 ml aliquots of the supernatant were distributed on microtiter plates and mixed with 100 ml of L-Dopa solution (2 mg/ml in PBS). After incubation for 5 h at 371C, the optical density (OD) at 570 nm was measured. Protein concentration in each extract was measured using residual 10 ml aliquots as described, 53 and the tyrosinase activity was standardized by the protein content.
Cell viability
Tetrazolium salt-based assay was performed as described previously. 70 Briefly, triplicate aliquots of cells were cultured in 96-well plates under standard conditions followed by addition of 20 ml of 0.5 mmol of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST8; Nacalai Tesque). After incubation for an additional 2 h, 100 ml of the supernatant was collected to measure the OD at 450 nm.
Real time RT-PCR analysis
RNA was extracted from cells and reverse-transcribed using an Omniscript RT Kit (Qiagen). The matching primers and dye probe were designed for the Mitf gene (forward primer: 5 0 -CCGACCCACTGCTGTCATC-3 0 , reverse primer: 5 0 -GCTCGCTAACACGCATGCT-3 0 , and TaqMan probe: 5 0 -CTTCAAAAACAAGCAGCCGG-3 0 ), while the b-actin-specific primers and probe were purchased from Applied Biosystems (Foster City, CA, USA). Real-time polymerase chain reaction (PCR) was performed using the 7300 Real-Time PCR System (Applied Biosystems, CA, USA), followed by quantification of RNA levels by RQ software (Applied Biosystems).
Western blot studies
Immunoblot analysis was performed as described. 33 Briefly, cellular extract containing 30 mg protein was separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). Mitf protein was probed with an anti-Mitf antibody, C5 (Sigma, Saint Louis, MO, USA), diluted at 1:250 followed by staining with an alkaline phospatase-conjugated anti-mouse immunoglobulin antibody (Stressgen Bioreagents, Victoria, Canada) diluted at 1:1000. The blots were developed with chemiluminescent substrate solution (Invitrogen, Carlsbad, CA, USA).
Tumor-bearing mice and siRNA transfection in vivo
Animal experiments were carried out in accordance with the institutional guidelines of the Kyoto Prefectural University of Medicine. To establish tumor-bearing mice, 5 Â 10 5 B16 cells were subcutaneously injected into the flank of female, 8-week-old C57BL/6 mice that had been purchased from Shimizu Laboratory Suppliers (Kyoto, Japan). After 3 days, tumors of an average volume of 10 mm 3 developed. A total of 20 mg of siRNA was diluted in 30 ml of DNase-free, RNase-free PBS and injected into each tumor using a syringe with a 27 G needle. Immediately after the injection, a pair of stainless-steel electrode plates of 10 mm in diameter was placed onto the tumor and electric pulses were given transcutaneously with an electroporater CUY21 (NeppaGene, Tokyo, Japan). Four square-wave pulses were delivered at a frequency of 1 s À1 with a pulse length of 50 ms and a voltage of 175 V/cm, followed by another four pulses of the opposite polarity. The tumor was then given an injection of another aliquot of siRNA solution (20 mg) and eight times pulsation as above. 
TUNEL staining
For TUNEL staining of the cells transfected in vitro, cells were cytocentrifuged at 300 Â g and stained with the MEBSTAIN Apoptosis Kit (Medical & Biological Laboratories, Nagoya, Japan). TUNEL staining of tumors was performed as described previously. 70 Briefly, tumors were fixed in 4% paraformaldehyde, embedded in optimal cutting temperature compound and immediately frozen at -801C. The specimens were cut into serial crysections of 10 mm thicknesses, followed by detection of apoptotic cells using the MEBSTAIN Apoptosis Kit.
Statistical analysis
Statistical comparisons of values were performed using Student's t-test.
